Trial Profile

Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 30 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dapagliflozin (Primary) ; Eplerenone (Primary)
Indications Proteinuria
Focus Therapeutic Use
Acronyms ROTATE 3

Most Recent Events

25 Jan 2024 Results of post-hoc anaylsis investigating investigate the effects of both agents alone and in combination on markers of the glomerular endothelial glycocalyx and tubular function,published in the Diabetes, Obesity and Metabolism
01 Aug 2022 Status changed from recruiting to completed as per results published in the Journal of the American Society of Nephrology
01 Aug 2022 Results published in the Journal of the American Society of Nephrology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com